Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008977 · ClinicalTrials.gov registry record · NA
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
A NA study of Cutaneous Melanoma and Merkel Cell Carcinoma, sponsored by AdventHealth Translational Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06008977 is a NA study of Cutaneous Melanoma and Merkel Cell Carcinoma that is actively recruiting participants, run by AdventHealth Translational Research Institute. The registered enrollment target is 20 participants, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06008977, a NA study of Cutaneous Melanoma and Merkel Cell Carcinoma, is actively recruiting participants, sponsored by AdventHealth Translational Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel cell carcinoma, scheduled to receive checkpoint blockade immunotherapy, and ii) preliminary data on the impact of a day-of-therapy exercise intervention.
Conditions Studied
Interventions
- OTHER Exercise Test
Study Locations (1)
Florida
- AdventHealth Translational Research Institute - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2025-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06008977
The ClinicalTrials.gov registry entry for NCT06008977 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (95% lower). The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Exercise Test is the first listed.
NCT06008977 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06008977 about?
NCT06008977 is a clinical study titled "Exercise to Boost Response to Checkpoint Blockade Immunotherapy". The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel cell carcinoma, scheduled to receive checkpoint blockade immunotherapy, ...
What is the current status of trial NCT06008977?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-06-03. Estimated completion is 2025-12.
What conditions does trial NCT06008977 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06008977?
The interventions under investigation include: Exercise Test (OTHER).
Who is sponsoring clinical trial NCT06008977?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06008977 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
ACTIVE NOT RECRUITING · NA
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RECRUITING · Phase 2
-
ACTengine® IMA203 Combined With mRNA-4203
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.